Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract (Q77428146)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9777318%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

review article

1 reference

title

Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9777318%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

author name string

H D Langtry

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9777318%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

H M Lamb

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9777318%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

publication date

1 September 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9777318%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9777318%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9777318%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9777318%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

page(s)

487-515

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9777318%20AND%20SRC:MED&resulttype=core&format=json

In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limits

5 December 2019

cites work

1 reference

12 December 2020

Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program

1 reference

12 December 2020

Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides

1 reference

12 December 2020

Making real sense of MRSA.

1 reference

12 December 2020

Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers

1 reference

12 December 2020

Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group

1 reference

12 December 2020

In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella

1 reference

12 December 2020

Effect of levofloxacin, erythromycin or rifampicin pretreatment on growth of Legionella pneumophila in human monocytes

1 reference

12 December 2020

Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin.

1 reference

12 December 2020

Levofloxacin selects fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus less frequently than ciprofloxacin.

1 reference

12 December 2020

Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of newer fluoroquinolones

1 reference

12 December 2020

In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains

1 reference

12 December 2020

Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus.

1 reference

12 December 2020

Streptococcus pneumoniae killing rate and post-antibiotic effect of levofloxacin and ciprofloxacin

1 reference

12 December 2020

Clinical pharmacokinetics of ciprofloxacin

1 reference

12 December 2020

In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia.

1 reference

12 December 2020

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

1 reference

12 December 2020

Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

1 reference

12 December 2020

Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo

1 reference

12 December 2020

Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill

1 reference

12 December 2020

Effects of antacid on absorption and excretion of new quinolones

1 reference

12 December 2020

A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection

1 reference

12 December 2020

The clinical pharmacokinetics of levofloxacin

1 reference

12 December 2020

In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae

1 reference

12 December 2020

Levofloxacin does not alter cyclosporine disposition

1 reference

12 December 2020

Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci

1 reference

12 December 2020

Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults

1 reference

12 December 2020

Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin

1 reference

12 December 2020

Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates

1 reference

12 December 2020

The choice of antibacterial drugs

1 reference

12 December 2020

Tolerability of fluoroquinolone antibiotics. Past, present and future

1 reference

12 December 2020

Levofloxacin and sparfloxacin: new quinolone antibiotics

1 reference

12 December 2020

Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America

1 reference

12 December 2020

In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.

1 reference

12 December 2020

Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin

1 reference

12 December 2020

Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of CS-940, a new fluoroquinolone, against isolates from patients with respiratory infections.

1 reference

12 December 2020

Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria

1 reference

12 December 2020

In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes

1 reference

12 December 2020

Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine

1 reference

12 December 2020

A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections

1 reference

12 December 2020

In vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1-ofloxacin

1 reference

12 December 2020

Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci

1 reference

12 December 2020

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

12 December 2020

In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae

1 reference

12 December 2020

In vitro activity of HSR-903, a new quinolone

1 reference

12 December 2020

In vitro activity of levofloxacin and FK-037 against aerobic isolates from spontaneous bacterial peritonitis

1 reference

12 December 2020

The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae

1 reference

12 December 2020

Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin

1 reference

12 December 2020

Antibacterial activity of AM-1155 against penicillin-resistant Streptococcus pneumoniae

1 reference

12 December 2020

In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

1 reference

12 December 2020

Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections.

1 reference

12 December 2020

Comparative in vitro activity of l-ofloxacin and FK037 to other agents against 10,040 fresh clinical isolates.

1 reference

12 December 2020

Treatment of skin and soft-tissue infections.

1 reference

12 December 2020

In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections

1 reference

12 December 2020

Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans

1 reference

12 December 2020

Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones

1 reference

12 December 2020

The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents

1 reference

12 December 2020

Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects

1 reference

12 December 2020

Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates

1 reference

12 December 2020

In vitro activities of Y-688, a new 7-substituted fluoroquinolone, against anaerobic bacteria.

1 reference

12 December 2020

Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers

1 reference

12 December 2020

The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci

1 reference

12 December 2020

In-vitro activity of ofloxacin, levofloxacin and D-ofloxacin against staphylococci

1 reference

12 December 2020

In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin.

1 reference

12 December 2020

Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods

1 reference

12 December 2020

Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.

1 reference

12 December 2020

Activities of ciprofloxacin, levofloxacin, ofloxacin and sparfloxacin against speciated coagulase-negative staphylococci sensitive and resistant to fluoroquinolones

1 reference

12 December 2020

Effect of paclitaxel alone or in combination on the intracellular penetration and activity of quinolones in human neutrophils

1 reference

12 December 2020

Comparison of lesions induced by intra-articular injections of quinolones and compounds damaging cartilage components in rat femoral condyles.

1 reference

12 December 2020

A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia

1 reference

12 December 2020

Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide

1 reference

12 December 2020

Comparison of the in vitro activity of levofloxacin and other antimicrobial agents against vancomycin-susceptible and vancomycin-resistant Enterococcus species

1 reference

12 December 2020

Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila

1 reference

12 December 2020

The postantibiotic suppressive effect of L-ofloxacin, an optically active isomer of ofloxacin.

1 reference

12 December 2020

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

1 reference

12 December 2020